Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders

Beacon Therapeutics CEO discusses VISTA trial results for XLRP gene therapy

29 min Listen to the original Episode page
Gene TherapyOphthalmologyBiotechClinical Trials

Summary

Lance Baldo, CEO of Beacon Therapeutics, discusses the company's focus on ocular gene therapy for rare and prevalent eye diseases. He highlights the pivotal VISTA trial for Larozova, which treats X-linked retinitis pigmentosa (XLRP), noting that 30% of patients gained three lines of vision on low luminance visual acuity. Baldo explains the clinical development path from earlier trials to the VISTA registration study. He also mentions the company's broader pipeline targeting geographic atrophy and inherited cone rod dystrophy.

Episode sections

  1. 0:00 – 2:29

    Introduction and Guest Background

    Host Tom Ryan introduces Lance Baldo, CEO of Beacon Therapeutics, outlining his background at Freenome, Adaptive Biotechnologies, Genentech, and The Medicines Company.

  2. 2:29 – 3:49

    Joining Beacon Therapeutics

    Baldo explains his move to Beacon Therapeutics after seeking a CEO role in ophthalmology, facilitated by a mentor.

  3. 3:49 – 4:51

    Company Focus and Pipeline

    Beacon Therapeutics focuses on ocular gene therapy for rare hereditary diseases and prevalent aging-related conditions like geographic atrophy.

  4. 4:51 – 5:38

    Market Size and Patient Demographics

    Baldo estimates hundreds of millions globally have blinding eye diseases, with ~2 million having inherited retinal diseases (IRD) and ~200,000 having XLRP in the US.

  5. 5:38 – 6:36

    Lead Asset Larozova and Mechanism

    Larozova treats XLRP by addressing RPGR gene mutations, causing photoreceptor dysfunction leading to vision loss.

  6. 6:36 – 8:06

    Clinical Results and Low Luminance Visual Acuity

    In clinical studies, patients gained 1-5 lines of vision. 30% of patients in the VISTA study gained three lines on LLVA.

  7. 8:06 – 9:07

    Path to Pivotal VISTA Trial

    Prior trials treated over 100 patients to determine optimal dose and delivery, supporting the launch of the pivotal VISTA study.

  8. 9:07 – 27:52

    VISTA Trial Results and Emotional Reaction

    Top-line VISTA results were announced on September 21st. Baldo describes an initial muted reaction followed by emotional realization of the medicine's impact.

  9. 27:52 – 28:23

    Company Vision and Pipeline Summary

    Baldo states his goal is to build the next great ocular gene therapy company. The host summarizes Beacon's pipeline targeting XLRP, geographic atrophy, and inherited cone rod dystrophy.

  10. 28:23 – 29:29

    Podcast Outro and Disclaimer

    Host concludes the episode. Standard disclaimer provided that stock references are not recommendations.

Claims worth verifying

Lance Baldo has served as CEO of Beacon Therapeutics since July 2024.

Unidentified speaker (UNKNOWN) ·1:24

How to verify: Check Beacon Therapeutics press releases or LinkedIn profile for Lance Baldo's appointment date. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

There are about 200,000 people worldwide living with X-linked retinitis pigmentosa (XLRP).

Lance Baldo ·5:33

How to verify: Cross-reference with epidemiological studies from NIH, Orphanet, or peer-reviewed journals on inherited retinal diseases. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

There are about 10,000 people with XLRP in the US alone.

Lance Baldo ·5:33

How to verify: Cross-reference with epidemiological studies from NIH or patient advocacy groups like Foundation Fighting Blindness. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

In the VISTA pivotal study, 30% of patients realized three lines of gain in low luminance visual acuity.

Lance Baldo ·7:15

How to verify: Review the official press release or clinical study report for the VISTA trial results announced by Beacon Therapeutics. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

VISTA trial top-line results were announced on September 21st.

Tom Ryan ·9:07

How to verify: Check Beacon Therapeutics press releases dated September 21, 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Luxterra achieved a positive pivotal readout in 2017, almost 10 years ago.

Lance Baldo ·12:05

How to verify: Check FDA approval dates or press releases for Luxturna (Spark Therapeutics/Novartis) which was approved in 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Beacon Therapeutics raised $170 million in Series B.

Unidentified speaker (speaker_1) ·21:46

How to verify: Check Beacon Therapeutics press releases or SEC Form D filings for the Series B raise amount. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Series C round was oversubscribed and included Goldman Sachs Alternatives.

Lance Baldo ·22:47

How to verify: Check Beacon Therapeutics press releases for Series C details and investor list. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Lance Baldo's goal is to build the world's great or next great ocular gene therapy company.

Lance Baldo ·28:12

How to verify: Check Beacon Therapeutics corporate presentations, investor day decks, or press releases for strategic goals and mission statements. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Beacon Therapeutics is a clinical-stage biotech company.

Unidentified speaker (speaker_2) ·28:24

How to verify: Verify via Beacon Therapeutics' official website, SEC filings (if public) or press releases detailing their development stage and pipeline status. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Beacon's pipeline targets X-linked retinitis pigmentosa, geographic atrophy, and inherited cone rod dystrophy.

Unidentified speaker (speaker_2) ·28:43

How to verify: Check Beacon Therapeutics' official website pipeline page or recent press releases announcing clinical trials for these specific indications. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Beacon Therapeutics is supported by a world-class cap table of investors.

Unidentified speaker (speaker_2) ·28:43

How to verify: Review Beacon Therapeutics' investor relations page or recent financing announcements (e.g., Series B/C) to identify institutional investors and check their track records. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify VISTA trial primary endpoint and statistical significance in the FDA briefing document or press release.
  • Check the definition and clinical relevance of Low Luminance Visual Acuity (LLVA) versus standard visual acuity.
  • Review Beacon Therapeutics' latest 10-K or 10-Q for cash runway and burn rate relative to VISTA follow-up costs.
  • Confirm the regulatory status of Larozova (IND, NDA, BLA) via FDA or EMA portals.
  • Assess the competitive landscape for XLRP treatments, including existing approved therapies or competing candidates.
  • Read the full VISTA trial results publication or abstract for detailed efficacy and safety data.
  • Verify the size of the XLRP patient population cited (200,000 US) against epidemiological studies.
  • Check for any conflicts of interest or related party transactions in Beacon Therapeutics' filings.
Full transcriptexpand

0:00Tom Ryan: Hey there, it's Tom Ryan, founder and executive chairman of ICR. Before we get into the next episode, I wanted to ask that you subscribe to the show. It'll help us get even more unique and interesting guests on the podcast, and in turn, continue to educate management teams and the growing ecosystem that creates value for fast-growing private and public companies. And while you're at it, head over to Apple Podcasts and leave us a five-star rating. Very much appreciated.

0:25Unidentified speaker (UNKNOWN): I

0:26Unidentified speaker (speaker_1): broke down crying. and I literally fell onto the floor in my bathroom because it finally hit me when I was seeing all this external validation that the company did it, that we did it.

0:35Unidentified speaker (speaker_2): Globally, there are hundreds of thousands of people living with X-linked retinitis pigmentosa, a devastating condition that often leads to vision loss in young people. And for the leader of Beacon Therapeutics, a company that's developed a promising new treatment, potential rewards. go way beyond profits.

0:52Unidentified speaker (UNKNOWN): I

0:52Unidentified speaker (speaker_1): told my team, we're not exactly sure how, we're not exactly sure when, but we now know with certainty that this medicine is going to help tens of thousands of patients around the world. And that is a really powerful feeling, Tom.

1:08Unidentified speaker (UNKNOWN): My

1:08Tom Ryan: name is Tom Ryan, and

1:09Unidentified speaker (speaker_2): this is Welcome

1:10Unidentified speaker (UNKNOWN): to the

1:10Unidentified speaker (speaker_2): Arena, the ICR podcast.

1:13Unidentified speaker (UNKNOWN): Each

1:13Unidentified speaker (speaker_2): week I

1:13Unidentified speaker (UNKNOWN): sit

1:13Unidentified speaker (speaker_2): down with

1:14Tom Ryan: today's business. leaders to give

1:15Unidentified speaker (UNKNOWN): you

1:15Tom Ryan: an inside scoop on some of America's most prosperous public companies, their origins, their challenges, and the

1:21Unidentified speaker (speaker_2): keys to their success.

1:24Unidentified speaker (UNKNOWN): Our

1:24Unidentified speaker (speaker_2): guest today is Lance Baldo, MD, who has served as the CEO of Beacon Therapeutics since July of 2024. Before Beacon, Lance was chief medical officer at Freenome, where he led medical strategy from clinical trials through registration and commercial. commercialization, and chief medical officer at adaptive biotechnologies, where he was part of the senior leadership team as it transitioned from private to publicly held company. Previously, he held numerous roles with the Roach Group, including SVP and head of U.S. Medical Affairs at Genentech, as well as franchise Chise head for ophthalmology. He also had roles of increasing responsibility at the Medicines Company. and founded the venture-backed medical software company, MedAptis. He is a medical doctor by training, holding an MD from the University of Connecticut School of Medicine, Go Huskies, and a BA in biology from Johns Hopkins University. Let's enter the arena with Lance Baldo.

2:29Tom Ryan: How did the Beacon Therapeutics opportunity come to you? What did you see in the potential of this whole endeavor? And what made you say, hey, listen, I'm going for this?

2:41Unidentified speaker (speaker_1): It's a great question. And I do

2:43Lance Baldo: believe in anyone's career, there's always a bit of kind of thought and planning, and then a little bit of luck as well. I'm a generalist, Tom. Like I worked across many different therapies. therapy areas. And as you know, just from reading my background now, I've worked in therapeutics, I've worked in diagnostics. Yep. I had decided that I wanted to kind of get back into therapeutics and specifically wanted to try my hand as a CEO. And one of the favorite parts of my career was running ophthalmology for Genentech. So I said, well, let's see. Beggars can't be choosers, but let's see if you can't find something suitable in ophthalmology. And an opportunity came my way, Tom, and I called a friend, mentor, and advisor of mine and said, Hey, I'm considering this opportunity in ophthalmology. And he said, Are you really thinking about a CEO job in ophthalmology? And I said, Yes, I am. He said, I think I've got one that's a better fit for you. And that turned out to be Beacon Therapeutics. And I got introduced to the investors, the current investors and the future investors. And it all went very quickly. Um, probably within a month of that phone call, I was signing an offer letter and then off to the races. with Beacon Therapeutics. It was really, really a good fit for me, Tom.

3:42Tom Ryan: Yeah, it's amazing how life works out like that sometimes. You never know where things take you with friends and and people you're close to in your circle. Maybe tell us about the history, the company, where it sits in the healthcare space, where it all kind of fits together for the audience.

3:57Lance Baldo: This is a an interesting space. It's ocular gene therapy and I'll explain a bit what that means. So these are genetic medicines. So there's a lot of diseases that have genetic origins or genetic etiology. And so what we're doing is we're fixing initially, especially a type of hereditary blindness. But the company doesn't only do that. We have a portfolio, we have a pipeline that includes these gene therapies, not just for a rare hereditary disease, but also more prevalent diseases. All of us take Tom, have a friend or a family member living with AMD or living with some of these eye diseases of aging. Our second asset that's also in the pipeline is to treat that prevalent condition that is called geographic atrophy. And so net net, we're all gene therapy. We focus mostly on the so-called back of the eye, which is the retina, which is kind of the business center of the eye. And we focus on both rare as well as more prevalent diseases.

4:51Tom Ryan: How many people are affected by these things worldwide?

4:54Lance Baldo: Yeah, the numbers are tremendous when you look at both the inherited as well as the blinding diseases that occur as you get older in life. And that's happening to all of us as we fortunately live a little bit longer and hopefully live a little bit healthier lives. But you're looking on the order of hundreds of millions of patients worldwide that live with these diseases globally. And even specifically, if you look at the inherited retinal diseases, I might use an acronym sometimes called IRD. These are the inherited retinal diseases. There's about two million people around the world living with these inherited retinal diseases as well. And with XLRP, which is the X-linked form of retinitis pigmentosa, there's about 200,000 of these people living around the world. And just in the US alone, there's about 10,000 of these, unfortunately, mostly young men. Aaron

5:38Unidentified speaker (UNKNOWN): Powell

5:38Tom Ryan: Talk about your lead asset and explain in simple terms maybe how it works and why you're so excited about it. Aaron

5:44Unidentified speaker (UNKNOWN): Powell

5:44Lance Baldo: The name of the product is called Larozova. So in this particular disease called X-linked retinitis pigmentosa, there is a certain protein, a gene that's mutated, and therefore that protein becomes dysfunctional or nonfunctional. And that protein is called RPGR. So in the absence of that particular protein, or in the case where that protein may be dysfunctional, the photoreceptors don't work properly. And what happens is early in life, not exclusively, but mostly young men, seven, eight, nine years old, they start to tell their parents, or their parents see them bumping into things. By the time they're in their teens, they're having a hard time reading. By the time they're in their 20s, it may no longer be safe to drive. And then in how half the time, by the time in their 40s, they actually hit legal blindness. And so this is a devastating disease that has currently no available treatment for them.

6:36Tom Ryan: Yeah. And I I was reading and this is like incredible, that once these photoreceptors start working again, patients could sometimes see three, four, maybe even five lines on the eye chart, whereas historically one line would be like a huge deal. I mean, that's why this is so exciting, right?

6:53Lance Baldo: It gives me goosebumps. I

6:55Unidentified speaker (UNKNOWN): mean,

6:55Lance Baldo: you're you're spot on. All of us for one reason or another have done an eye chart. I mean, I'm wearing glasses as you can see, but the audience can't. And so I know what it means when you can gain a letter or a line, but you're absolutely right. In these clinical studies, we're seeing patients that are gaining one, two, three, four, even five lines of additional vision in some cases, a full three. 30% are realizing three lines of gain in the pivotal study, the VISTA study we're gonna talk around later. I mean, these are life-changing types of improvements, what we call clinically meaningful. I will also clarify this is a certain type of vision called low luminance visual acuity, or you'll sometimes hear me say LLVA for short. Yep. And this is how well you see in low light conditions. And what I often like to tell people, a significant portion of your life is lived in low light conditions. And

7:43Unidentified speaker (UNKNOWN): so

7:43Lance Baldo: this is incredibly important for people to be able to navigate daily life and be able to continue to be constructive and continue to have meaningful lives.

7:51Tom Ryan: So I know you've built up five years of clinical experience with Larozova across horizon, skyline, Line and dawn trials, right? Over a 100 hundred treated participants. How did that body of work? set the stage for VISTA, which is really your pivotal trial?

8:06Unidentified speaker (UNKNOWN): Yeah,

8:06Lance Baldo: this is, as you point, a very large body of data for what we like to call a rare but not ultra rare disease. And so over 100 patients treated, we have close to 130 eyes that have been treated as well. And what we did was in those early studies, you do things like try to figure out what's the right dose. Is that dose likely to be safe? and hopefully efficacious? What's the right place to put the medicine in the back of the eye? One of the things we didn't mention, this medicine is delivered by a needle. It's called subretinally. So a needle gets put into the back of the eye, and we deliver the medicine locally to the retina. So therefore those photoreceptors will actually take up the medicine. So some of the early studies helped us figure out where's the right place to actually put this medicine. And then ultimately, once you say, all right, now I think I've got the right dose. I think I've got the right location, that's when we launched the so-called Pivotal VISTA study, which is the key study that's intended to support worldwide registration. So how that's how you get the regulatory authorizations so that you can then move to commercialize this medicine and make sure it can get to patients.

9:07Tom Ryan: Yeah. And I know that you announced positive top-line top line results from the VISTA trial on September 21st. twenty first. You had been waiting for

9:14Unidentified speaker (UNKNOWN): the first time.

9:15Tom Ryan: on those results for literally years, right? Um and then you got the call. Where were you

9:23Unidentified speaker (UNKNOWN): when

9:23Tom Ryan: the phone rang? How did you feel that day? Like, take us through it.

9:28Lance Baldo: I'm

9:28Unidentified speaker (speaker_1): gonna correct you on one thing, and it's

9:30Lance Baldo: my team corrected me as well. We weren't waiting for the data, we were getting prepared for the data because it's a ton of work to get ready for those data.

9:36Tom Ryan: Got it. There you go.

9:36Unidentified speaker (UNKNOWN): And

9:36Lance Baldo: actually the call came in a little later than expected, which kind of scared me at first because the team said they need a little more time. And I thought, oh my goodness, does that mean it's gonna be bad news? But when I saw that initial text and then the phone call from our chief medical officer, I said to Dan, I said, I'm gonna close my eyes while you tell me what the results are. I said, Because I just can't even keep my eyes open. And then he gave me the results, and I will say my my reaction was pretty muted. And I think part of that was, and I bet many people in my position would feel similarly.

10:06Unidentified speaker (UNKNOWN): We

10:07Lance Baldo: went immediately to action mode. It was like, all right, press release, tell our investors, get ready to engage with the regulators. Let's start to get more prepared for the commercialization.

10:15Tom Ryan: Yeah.

10:16Lance Baldo: The powerful moment for me, Tom, and I tend to be a pretty emotional leader. I cry when I'm sad, I laugh when I'm happy. I

10:22Tom Ryan: love it.

10:23Lance Baldo: When the price release came out, and thanks to ICR for all their support with that. as well, it had to be released in essentially what was the middle of the night for me. I live on the west coast of the US. I decided to set my alarm and wake up incredibly early at about three AM because I wanted to see the news flow in real time.

10:39Unidentified speaker (UNKNOWN): Yeah.

10:39Tom Ryan: I

10:39Lance Baldo: went to my desk and I watched all this really positive news flow and all the congratulatory emails, and it really felt good for about an hour. And then I went into my bathroom just to kind of collect myself and I might get emotional now, and I just started crying. Yeah.

10:51Tom Ryan: I

10:51Lance Baldo: broke down crying and I literally fell onto the floor in my bathroom because it finally hit me when I was seeing all this external validation that the company did it, that we did it. And now I knew and I told my team, we're not exactly sure how, we're not exactly sure when, but we now know with certainty that this medicine is going to help tens of thousands of patients around the world. And that is a really powerful feeling. But it took me a good three weeks before it finally hit me. And I was remember thinking to myself, I hope my wife doesn't wake up and see me in a puddle

11:20Unidentified speaker (UNKNOWN): on the

11:21Lance Baldo: bathroom floor because she's going to think, what is going

11:23Unidentified speaker (UNKNOWN): on

11:23Unidentified speaker (speaker_1): right now?

11:24Tom Ryan: Yeah. Yeah. Well, listen, I think having an emotional leader is a great thing. You know, you gotta wear your heart on your sleeve. And it's not like you're just making widgets, you know, you're doing something that can really improve people's lives. And I would imagine the magnitude of that hit you at that moment. because it's not just about like investors, and of course that's important, but you know, tens of thousands of millions of people around the world, they they wouldn't even know what just happened, right? But they're gonna find out over time. Why hasn't anyone else been able to create kind of a successful ocular gene therapy? And I I believe Luxterna did it in 2017, almost 10 years ago. Why hasn't anyone else been able to do that in your opinion?

12:05Lance Baldo: I think, Tom, that's exactly what makes this milestone so meaningful. As you already pointed out, it's been a decade since the last product read out positively in a so-called pivotal uh study as well. I think there's a number of reasons for that. We learn and we get smarter. And and I like to say, because I think it's a nod to all the great work that was done before us, we're standing on the shoulders of giants. Um it wasn't necessarily always obvious how you need to improve upon some of these gene therapies. Yeah.

12:31Unidentified speaker (UNKNOWN): What's

12:32Lance Baldo: the right capsid? What's the right wrapping for the therapy? What's the right gene? You know, in other words, what do you want to code for within that gene? And then I already mentioned how would you deliver it? Where's the right place to put this medicine? So over the last few years, we've worked to improve that. And maybe just as importantly, there's two things that Beacon, my predecessors as well as my team have done really well. is design the right study, getting the right patients in that study. And really importantly, and you've picked up on this in your early questioning, picking what I call a discriminatory endpoint, an endpoint that's likely to show whether or not this medicine works, and do it on some kind of a measure that's going to be clinically meaningful for patients. And that was the so-called low luminance visual acuity. This is the first study within this disease to prospectively look. at low luminance visual acuity in the context of a pivotal study. And it turns out that it looks like it was certainly the right decision. And we didn't make it blindly, Tom. There was some early work that we did in phase two that showed that La Resova was moving the needle on this measure called low luminance visual acuity. And so we felt a lot more confident in our choice of that endpoint Point for the so-called pivotal Vista study, Tom.

13:35Tom Ryan: Yeah. What's been the reaction from kind of the retinum? retinin scientific communities, like from patients and you know, obviously the investment community, it's a huge deal as well, including recent Fierce 15 recognition and maybe explain what that is. Yeah,

13:49Lance Baldo: I'm gonna try to keep this short, but this is where like I still I still feel like I'm living on a bit of a hype, particularly after the American Academy of Ophthalmology, where we had the data presented at a the laybreaker. I've worked in and out of ophthalmology for a number of years, and it's a small community. so I'm relatively known just because I know a lot of people, a lot of people know me. And just walking around the convention center, people coming up to me and saying, Congratulations, Lance, we're so happy for you. And even thank you. Wow. I had numerous leaders in our industry saying, thank you. This is the win that we all needed, because a rising tide is going to float all ships. Thank you for pioneering this endpoint. Thank you for making sure that that this industry gets the recognition. that it deserves. Very powerful moments. I mean, for anyone, ego or no ego, it's nice to have that validation. And one you mentioned patience, and I'll give you one anecdote about a a parent, emotional email from a parent who just said, thank you. And and I think really importantly, while she recognized that we were obviously very happy, she said, you have no idea what this actually means to a

14:49parent or a child. living with this condition. When you haven't seen it firsthand, you really can't appreciate it. Yeah. And it was a very powerful moment for us. And we actually, in a confidential way, shared that with the whole company as well. Because it's these really powerful moments. You know, you you use the word I like to use a lot. We don't build widgets.

15:06Tom Ryan: Yeah.

15:06Lance Baldo: These are real medicines that help real people that are otherwise going gonna to have almost nothing that's going gonna to make their site better. And so you just have to like every day recognize how important the work that we do

15:17Unidentified speaker (UNKNOWN): is at

15:20Unidentified speaker (speaker_2): this point. I asked Lance to explain what those designations actually mean and how they shape the regulatory pathway as Beacon works towards bringing that drug to market.

15:38Lance Baldo: There's a little bit of an alphabet soup of the worldwide regulatory designations.

15:43Unidentified speaker (UNKNOWN): Yeah.

15:43Tom Ryan: Yeah.

15:43Lance Baldo: But I think in summary, they give you a different level of access with the regulators. Because the regulators, you know, meaning the European and particularly the US regulators, have said that this medicine likely has and possibly has real clinical benefit. And so you get better access with the regulators. And I do want to provide some. commendation to them. They've been great throughout this process.

16:05Tom Ryan: Yeah.

16:06Lance Baldo: Probably engaged a little more as of late with the FDA than the European regulators, but they've been really meeting our expectations in terms of getting us the feedback that we need. You can't do this work in a vacuum. If you don't know where you're heading towards and what kind of the guardrails are, it's impossible to do the work that we do. And so we've been very fortunate that, partially just based on the good engagement, the great engagement of these regulators, but also. these regulatory designations, we've been able to get the feedback all along the way. You know, is this an adequate study design? Is the study adequately powered? Are these the right endpoints to support registration? And once you get that confidence from the regulators, you can then proceed down that path with a lot more confidence. And also, by the way, for me as a CEO, Tom, Um raise money. Yeah. We can't do this without capital, right? And so we need to not only instill confidence in ourselves. but also that external investment community who gives us the all-important capital so that we can go after these opportunities as well.

16:58Tom Ryan: 100%. And I know you recently began a landscape trial or the landscape trial, looking to treat both eyes. Why is that so important and how does it fit into the long-term plan for Larozova? Larazova. Trevor

17:10Unidentified speaker (UNKNOWN): Burrus

17:10Lance Baldo: Most of the studies that we'd done prior were either single-eye studies, in other words, just injecting one of the two eyes in these subjects in these patients. Yep. Or the second eye was treated many months or many years after the first eye. We wanted to establish not just the efficacy, but also the safety of giving the medicine in one eye pretty soon after the second eye. Call it about seven to ten days or so, because ultimately we're binocular beings. Yeah. This disease affects both eyes. And often these patients, they kind of want to get treated about the same time. This will be a so-called center of excellence type treatment approach. Every single hospital is not going to have someone that's going to be able to administer this medicine. And so you're going to have to go to one of these centers. And when you do go, you want to ideally get both eyes treated in a relatively short period of time. So that's what the landscape study is doing for us, showing us that it's safe to administer the medicine first in one eye and then in the second eye. safely.

18:04Tom Ryan: How do you go about like thinking about the go-to-market strategy and launch readiness? You know, Larozova would be your first commercial product. Like as you take the steps to put the apparatus in place, how do you think about go to market?

18:18Lance Baldo: Yeah, and Tom, we've been working on this for almost the better part of my tenure now, which has been a couple of years. Obviously, the

18:24Unidentified speaker (UNKNOWN): early

18:24Lance Baldo: work you do is a little bit more planning and thinking. and kind of a ga engaging externally to see what it's actually gonna take. And many of our investments you wouldn't be surprised to know were gated upon the positive readout. Yeah. Because you need to be cautious as a privately held company how much you can invest before you know what kind of a product you've got in hand. So now that we have those data in hand, we're really, really working on some of those planning steps in earnest at this point now. And if anyone tells you there's a such thing as an easy launch, that's completely a fallacy. So there's no such thing as an easy launch. Yeah.

18:53Unidentified speaker (UNKNOWN): But

18:54Lance Baldo: when you look at the continuum of the types of launches, you know, this is a population where you can find them. It's well defined. As I mentioned, it's a center of excellence approach. And so l very likely there may be 30, 40, 50 of these treatment centers in the US. So it's possible to engage with in meaningful ways with them. And so we're already doing the work, by the way, to start thinking through. you know, what would the rollout look like? Who are the centers? How are we going to qualify them? And then it's not just about the centers and the sites. This is a medicine that's administered by a surgeon. Often this patient is being treated by a so-called IRD specialist. So there's also care coordination. And these are therapies that just generally aren't kept in the freezer all the time, right? Yeah. And so we also have to think about supply chain and how do you get the medicine, hopefully just in time, to these sites and these centers that wanted to administer them as well. And those are all the things that we're working on right now. But again, as a private company, no such thing as an easy launch, but you can imagine raising the private capital to be able to do this launch yourself, especially in the US, likely in Europe. Outside of that, it's unlikely we'd ever build the infrastructure for parts of Asia, parts of South Africa, America. Yeah. But in the larger markets closer to home, it's something that you could absolutely do as a privately held company. That being said, we're keeping all of our options open, including exploring the potential for

20:13partnerships throughout the world.

20:15Tom Ryan: Yeah. And then to make things even more complex beyond XLRP, I know the pipeline includes, you mentioned it earlier, geographic atrophy, inherited cone rod dystrophy. How does the progress there? with Larozova shape that broader pipeline strategy with you all?

20:31Lance Baldo: Yeah, so we kind of hope that we can move things in parallel. For the phase we're at right now with some of those other pipeline products, it's definitely feasible for a company of our size. But as we do think about raising capital, that capital will also be used to help invest in some of those assets that you've already described, and particularly the GA asset design. the geographic atrophy asset, which is moving into the clinic very soon. And so we've got what's so-called IND clearance or investigational new drug clearance with the FDA. And we're getting prepared now to dose the first patients within the phase one dose finding study for that therapy as well. So it's kind of an and and not an or, even though for a company of our size, you do need to be thoughtful about where you're spending your time. Eventually, should some of those products move into the larger studies that might be required, we would have to rethink, you know, capital needs and would you partner or not? But that stuff is many months, if not many years down the road.

21:26Tom Ryan: Yeah. And uh boy, in this environment of AI and everything, like raising capital is That's very critical. I know you raised 170 million in Series B. You had an oversus. oversubscribed Series C round. Take us through your experience with raising capital and who were some of the names in your cap table.

21:46Unidentified speaker (speaker_1): I'll tell you one funny, I guess I get at least I think it's funny anecdote or story.

21:50Tom Ryan: I'll think it's funny.

21:51Unidentified speaker (speaker_1): Thank

21:51Unidentified speaker (UNKNOWN): you for that

21:51Tom Ryan: time.

21:57Unidentified speaker (speaker_1): Which I now am, of course, a first-time CEO. I remember one of my CEO friends and colleagues telling me, um, your primary job is raising money. And I was like, Well, you know, you have to operate the business. He said, No,

22:08Unidentified speaker (UNKNOWN): your

22:08Unidentified speaker (speaker_1): primary job is raising money. And you know what I've come to find out? Your primary

22:12Lance Baldo: job is making sure that you keep the company capitalized. Like, yes, you have to operate the business and make sure you have great people around you. Yeah. But ultimately, you and only you are the top person And responsible for making sure you keep money in the bank to pay the bills so that you can go after the opportunities in front of you. And I that was really it took a while for that to sink in for me. We've been very fortunate that we have, number one, already a really good syndicate of investors who have, as we've moved forward and made more cro progress, have committed that they would stick with us through the later funding rounds. And in fact, including the Series B investors participating in the Series C. Also thankful that Goldman Sachs alternatives came in on the series. C for what ended up being an oversubscribed round. And so that was really great because that was enough capital to take us through the Vista readout that we we just talked about, and also sometime into next year as well. But we do have to raise capital again. We're not in a situation where you raise such a large magnitude of capital that you're going to have many, many, many years of runway. But we have great investors. Syncona, Forbian, Advent License. Life Sciences, TCGX, and Goldman, just to name a few. So very, very thankful for the syndicate we have that not just bring the money to the table, but also the knowledge and technical know-how about company formation

23:27and company building.

23:28Tom Ryan: What's been your biggest challenge since you took the role at Beacon?

23:31Lance Baldo: You know, I am. I consider myself to be an entrepreneur, and I always try to lead as if I've got the mindset of an entrepreneur. And that does mean that the high highs are incredibly high and the lows can be incredibly low. You tend to take things very, very personally when they go well and when they sometimes don't go well. Yeah.

23:46Unidentified speaker (UNKNOWN): I

23:46Lance Baldo: think the harder part to me was a little bit related to what I said just a moment ago. I I don't want to sound overly cocky or confident, but operating the business is pretty manageable because I've been doing that for 25 years of

23:58Unidentified speaker (UNKNOWN): my

23:58Lance Baldo: career, is like, you know, at different levels and in different places, operating businesses. And so that part comes a little bit easier. What I mean by that is just the day-to-day of making the company kind of hum. The harder part has been dealing with all the constituents you have, because now all of a sudden you have investors, board members, there's a whole finance community, including bankers and analysts. And so learning how to deal within that ecosystem was a challenge for me. And not necessarily because it's you know necessarily hard, it's just new. And I hadn't done that in the past in my career. And like I said, I have great investors, but still, like, you know, there's still a lot of stakeholders that you need to engage with. In fact, some people will, you know, tell me errantly, like, you know, you don't have how does it feel to not have any bosses? I have many more bosses than most people because I have these, you know, for all the right reasons, demanding investor directors. They put a lot of money into this and they deserve to be kept informed. And they deserve to think and know that we're going about this the right way. And so I don't have one bosses. I have multiple bosses and uh that comes with challenges unto itself.

24:59Tom Ryan: Yeah. And listen, it can really take 10 or 20% of your time if you don't control your schedule and be organized and have a process to kind of get through the day because the most important thing is running this business. But then all of a sudden you're like, wow, I have another 10 to 20% of my time that I have to be doing like over here. And managing that is a real trick, you know. I mean, because if you let it get out of control, your schedule can be bananas, you know.

25:23Lance Baldo: Some my number's 20%. Like I've been asked in the past, how much time do you think you spend on the things that we were just discussing? And the number I've thrown out there is about and now occasionally there's weeks or months where maybe it's much lower. And there's weeks or months, I can tell you in the throes of fundraising, yeah, it's probably 30 thirty to forty 40% percent of my time. And I'll never forget closing the Series C because I was on DocuSign two days before Christmas, like literally signing things, you know, right in the lead up to Christmas Eve.

25:47Tom Ryan: Yeah.

25:48Lance Baldo: But it was important. And I wanted to get it done. And I wanted to put that behind me and have a good holiday, you know, with my family and with my friends. For

25:54Unidentified speaker (UNKNOWN): sure.

25:55Lance Baldo: But sometimes you just need to, in your career, make those sacrifices. And it was a worthwhile sacrifice, particularly in light of the amazing positive news that we've had of late, it makes it all worth it. all the sacrifice worth it.

26:04Tom Ryan: Well, listen, we're here at the end of 2026, looking into 2027. And uh I always think like a great management team can only do one or two or three things like really well in any given year. What is your area of focus? What's everybody pumped up about as we look into 2027? What are the two or three things that you're really zeroed in on?

26:24Lance Baldo: We're so myopically focused on the next couple of years. quarters. And it's pretty clear what we need to do. We need to kind of make sure that we fully understand these VISTA data. We need to engage with the regulators and begin the process of moving to authorize this product around the world. And we need to do the commercial readiness to get ready to launch this product and make sure that we can get it as expeditiously as possible into the hands of physicians and then ultimately into the back of the eye of these patients. So three things. Understand the data, engage with the regulators, and get ready to commercialize it. Oh, and that probably that fourth thing is raise money.

26:57Tom Ryan: I was the CEO of ICR for 27 years. And in my mind, I always had the perfect vision for what we wanted to be. And I always felt like we could never get there perfectly. When you are by yourself thinking about the company, which I'm sure you think about 24-7, 365, you look out. five years. What would be like the ultimate place for beacon therapeutics to be in your mind? What are you guys doing? Where are you in the marketplace? What's happening?

27:25Unidentified speaker (speaker_1): When I took this job a little over two years ago, my personal vision, which

27:30Unidentified speaker (UNKNOWN): I

27:30Unidentified speaker (speaker_1): wrote down for myself, I'll often sometimes write down little notes

27:32Lance Baldo: to myself, is that we were going to build. And I mean we because it was our investors, all the other staff around me and myself. the world's next great, or maybe the great ocular gene therapy company. Um, you know, focus on the eye, focus on gene therapy, but build an absolutely great company around that. I think now on the back of these data, we certainly have the possibility to do that, particularly with a pipeline behind it. But you never know. You know, what the future holds is nearly impossible to predict. But I'm a big believer, and it sounds like you led ICR the same way. If you march in that direction and can get everyone marching with you in that direction, you're going to be prepared for any eventuality that comes your way, even if it's one that I'm not contemplating today. So my goal remains to build the world's great or next great ocular gene therapy company.

28:23Unidentified speaker (UNKNOWN): That

28:24Unidentified speaker (speaker_2): was Lance Baldo, MD, CEO of Beacon Therapeutics. They're a clinical stage biotech company, and they are positioned to harness the transformative power of gene therapy to restore sight for people living with rare and prevalent ocular diseases. Beacon's Pipeline currently targets devastating blinding diseases including X-link, retinitis pigmentosa, geographic atrophy, as well as inherited cone rod dystrophy. and they're making progress supported by a world-class cap table of investors, as well as world-class execution, which is the name of the game. I'm Tom Ryan. We'll see you next time back in the arena.

29:02Tom Ryan: References to specific stocks are not intended to be recommendations for specific trading behavior. Comments presented on this podcast are intended for informational and educational purposes only, and do not represent opinions or recommendations on whether to buy. sell, or hold shares of a particular stock. All investors are advised to conduct their own independent research into individual stocks before making a trading decision. In addition, investors are advised that past stock performance is no guarantee of future price performance.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights